Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pivotal phase III Kiobrina study does not meet primary endpoint

March 31, 2014

Phase III fertility study of Pergoveris in poor ovarian responders begins

March 31, 2014

Gemigliptin/metformin fixed-dose combination shows promise in healthy volunteers

March 28, 2014

Pfizer achieves primary endpoint in phase IIIb study of Genotropin

March 28, 2014

First patient enrolled in phase IIa trial of ORMD-0801 in type 1 diabetes

March 28, 2014

Albiglutide approved in Europe for type 2 diabetes

March 27, 2014

Results presented for the novel xanthine oxidase inhibitor LC-350189 in humans

March 26, 2014

Tofogliflozin hydrate approved for type 2 diabetes in Japan

March 26, 2014

Japanese approval of Lusefi for type 2 diabetes

March 25, 2014

Forxiga receives regulatory approval in Japan for type 2 diabetes

March 25, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...